Aztreonam pharma-grade active pharmaceutical ingredient is a synthetic monocyclic beta-lactam (monobactam) antibiotic. The substance is designated by CAS 78110-38-0 and is described by the molecular formula C₁₃H₁₇N₅O₈S₂, with a relative molecular mass of 435.43 g/mol. The API is supplied as a white to off-white crystalline powder. The non-sterile oral solid dosage grade is intended for tablet, capsule, and granule development; the sterile injection and inhalation grade is micronized and controlled for bacterial endotoxin, bioburden, and sub-visible particulates. The product is not a bicyclic beta-lactam; its monocyclic structure restricts activity to susceptible aerobic Gram-negative bacteria by selective binding to penicillin-binding protein 3.

Grade differentiation is based on end-use. The oral grade is typically non-sterile and has a larger particle size distribution. The sterile grade is micronized and may be supplied as the anhydrous free acid or as the lysine salt for nebulizer solutions, depending on the manufacturing route. The solid-oral grade is controlled to a D₉₀ below 250 µm, while the sterile micronized grade is controlled to a D₉₀ below 50 µm. Particle size is measured by laser diffraction under ISO 13320. Bulk and tapped density are measured by USP <616>. Parenteral grade specifications for endotoxin, sterility, and particulate matter are not interchangeable with oral grade specifications. The manufacturer release certificate should state the grade code, salt form, particle size D₉₀, residual solvent profile, polymorphic form, and compliance with the applicable monograph.

What limits the use of oral aztreonam granules in systemic therapy?

Oral aztreonam has poor gastrointestinal absorption. The compound is minimally absorbed across the intestinal epithelium; therefore a tablet or capsule cannot be treated as a systemic dosage form absent a validated absorption-enabling formulation. Published pharmacokinetic data for oral solid dosage forms of aztreonam are limited. Any development of oral granules, tablets, or capsules should be restricted to local gastrointestinal antimicrobial studies or to formulation feasibility work. If an oral batch is manufactured, dissolution testing should follow USP <711>, but an in vivo bioequivalence standard cannot be established from compendial dissolution data alone.

Granulation trials are constrained by the hydrolytic lability of the monobactam ring. High-shear aqueous granulation introduces a degradation risk. The beta-lactam carbonyl is susceptible to nucleophilic attack by water, particularly at pH below 2.0 and above 8.0. Published kinetic data for aztreonam hydrolysis in aqueous granulation matrices are limited; the pH boundaries given are consistent with general beta-lactam degradation behavior and should be confirmed by ICH Q1A(R2) forced-degradation studies. For any wet granulation, the granulation endpoint should be held at residual moisture below 2.0% and the drying temperature should not exceed 45°C during tray drying. Roller compaction and direct compression are lower-risk alternatives because they avoid the aqueous granulation step.

Compendial Identity and Physicochemical Release Attributes

The compendial identity of aztreonam is established by infrared absorption and liquid chromatography. USP <197K> and Ph. Eur. 2.2.24 are used for IR spectral matching; HPLC retention time is compared with the reference standard under USP <621> and Ph. Eur. 2.2.29. The release specification includes assay, related substances, water, residual solvents, elemental impurities, and, for the parenteral grade, bacterial endotoxin and sterility. The assay range is typically 97.0–102.0% on the anhydrous basis, with related substances controlled according to ICH Q3A reporting, identification, and qualification thresholds.

Related compound control is important because aztreonam synthetic routes can generate open-ring amide impurities and residual solvents such as ethanol, isopropanol, or acetonitrile. USP <467> and ICH Q3C residual solvent limits apply. Elemental impurities are measured using USP <232> and USP <233> with limits per ICH Q3D. The crystal form should be confirmed by X-ray powder diffraction; the material is crystalline and monomorphic, but drying at elevated temperature may alter the pseudo-polymorphic hydration state if a channel hydrate is present. For the sterile grade, the certificate of analysis should also include bacterial endotoxin and sterility data.

The table represents the minimum release package; a specific manufacturer may impose tighter limits based on process capability. The solid-oral grade is not acceptable for injection because it is not controlled for bacterial endotoxin and sub-visible particulates. Conversely, the sterile grade may be used for oral dosage forms only if the micronized particle size is suitable for the intended solid dosage process; otherwise, the oral grade is preferred.

When the API Is Destined for Injectable Use, Endotoxin and Particulate Control Dominate

For injectable manufacturing, aztreonam is commonly supplied as a sterile micronized powder for reconstitution, or as a sterile bulk solution for aseptic filling and lyophilization. The monobactam ring is not sufficiently stable at neutral pH under prolonged autoclave cycles, so terminal sterilization is generally replaced by aseptic processing. The API should be dissolved in Water for Injection, filtered through a 0.22 µm polyvinylidene fluoride or polyether sulfone membrane, and filled under ISO 5 conditions. The solution may be lyophilized; the freeze-drying cycle should maintain product temperature below collapse temperature and limit residual moisture to a value consistent with the approved stability protocol.

The endotoxin specification for the API is derived from the maximum intended daily dose. With a maximum parenteral dose of 8 g/day, USP <85> yields a limit of 0.044 EU/mg. This requires a depyrogenation strategy in the final crystallisation and drying steps; a Water-for-Injection final rinse and hot-air depyrogenation of contact surfaces are used. Hot-air depyrogenation of contact surfaces is commonly performed at 250°C for 45 min; the chosen parameters must be validated against a 3-log endotoxin reduction. The API itself cannot be dry-heat depyrogenated without excessive degradation, so depyrogenation must be achieved in solution by filtration or by process controls in final crystallisation and washing. Particulate matter is controlled by sterile filtration and by laser obscuration counting on reconstituted solutions according to USP <789> for small-volume injections. Incompatibilities should be screened when aztreonam is combined with other injectables; visible precipitation has been reported with metronidazole and nafcillin, so these admixtures should be avoided unless specific compatibility data demonstrate otherwise.

For inhalation grade, the lysine salt is commonly used because of its pH and osmolality profile. The micronized powder is filled into unit-dose vials under low-humidity conditions; the target delivered particle size distribution for nebulization is typically a D₅₀ below 3 µm, but the final droplet size is governed by the nebulizer type, not only the API particle size. Batch-to-batch control includes particle-size distribution by laser diffraction, water content by USP <921>, and sub-visible particle counts after reconstitution in Sterile Water for Injection.

Processing tablets and capsules below the aqueous hydrolytic threshold

The oral solid dosage grade is processed into tablets, capsules, or granules primarily for formulation research and non-systemic local delivery. Direct compression with microcrystalline cellulose and lactose blends is possible if the API flow properties are acceptable; however, when the Carr index exceeds 30, roller compaction should be introduced before tableting. A tablet press with precompression and force control is recommended because the API is cohesive and may exhibit sticking on steel punches. Punch lubrication with magnesium stearate at 0.5–1.0% w/w is typical; higher concentrations may reduce tensile strength and delay dissolution.

Wet granulation is a high-risk operation due to beta-lactam hydrolysis. If a wet granulation is unavoidable, the binder solution should be non-aqueous or have low water activity, and the final drying step should be performed in a vacuum dryer at product temperature below 45°C. The resulting granules should be characterized for related substances by HPLC before compression. For capsule filling, an automatic capsule machine with a tamping pin or dosator configuration is used; the fill weight uniformity should meet USP <905>. Granule bed water activity should be measured because water activity above 0.45 increases degradation risk during short-term holding. Published data for this specific configuration are limited; however, standard powder technology practice indicates that granule fines above 30% w/w can increase tablet weight variation. Dissolution testing should be performed in a medium selected for sink conditions and degradation control; if the compound degrades in acidic media, a two-stage medium with phosphate buffer pH 6.8 may be necessary. Since the oral bioavailability of aztreonam is negligible, dissolution data do not predict systemic exposure; any in vivo oral study requires a validated bioanalytical method for aztreonam and its open-ring hydrolysis product.

In comparison to bicyclic beta-lactam APIs such as ceftazidime, meropenem, and piperacillin-tazobactam, aztreonam has a narrower spectrum. The structural difference is the absence of a fused bicyclic ring system; the sulfamic acid and thiazol heterocycle are maintained, but the beta-lactam ring is not fused to a sulfur-containing thiazolidine or dihydrothiazine ring. This changes the hydrolysis profile. Aztreonam is generally stable to some metallo-beta-lactamases but can be hydrolyzed by many serine beta-lactamases, including extended-spectrum beta-lactamases and some carbapenemases; combinations with beta-lactamase inhibitors such as avibactam are therefore evaluated where multi-drug-resistant Gram-negative isolates are present.

The API should not be considered interchangeable with ceftazidime or carbapenems in clinical or formulation use. It lacks the Gram-positive and anaerobic activity of meropenem and piperacillin-tazobactam. This narrow spectrum may reduce collateral selection pressure on enterococci and obligate anaerobes, but it also limits empirical monotherapy to known susceptible Gram-negative infections. Formulation of aztreonam with a beta-lactamase inhibitor requires separation of the two components if the inhibitor is incompatible with the monobactam ring under acidic conditions.

The product differs from many other beta-lactam APIs in its route-dependent formulation requirements. The injectable grade is not a direct substitute for cephalosporin or carbapenem sterile APIs in terminally sterilized admixtures because monobactam degradation kinetics differ. Aztreonam should be stored in a dry, airtight container and protected from moisture. The manufacturer should be audited under ICH Q7 and FDA 21 CFR Part 211 for sterile grade. For oral grade, current Good Manufacturing Practice for active substances is required; the absence of a compendial oral monograph for aztreonam tablets does not waive the obligation to control related substances and assay.